"I have dozens of friends who’ve shut down or are facing bankruptcy," says Uta Mühle. "And then almost daily, I have to tell someone they’re no longer welcome in my pharmacy"
The pharmaceutical sector in the EU faces unprecedented supply chain vulnerabilities rooted in supply concentration, particularly for off-patent medicines, as on recent report (open pdf) has found:
Over 40% of off-patent active pharmaceutical ingredients (APIs) globally are sourced from China – with nearly all API producers relying on Asia-based manufacturers for intermediate inputs.
Let’s hope that the EU’s Critical Medicines Act is going to change the situation.
The pharmaceutical sector in the EU faces unprecedented supply chain vulnerabilities rooted in supply concentration, particularly for off-patent medicines, as on recent report (open pdf) has found:
Let’s hope that the EU’s Critical Medicines Act is going to change the situation.